BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38645565)

  • 21. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative Lower Body Mass Index Correlates with Poorer Prognosis in Patients Undergoing Curative Laparoscopic Surgery for Colorectal Cancer.
    Uratani R; Toiyama Y; Shimura T; Mori K; Fujikawa H; Hiro J; Ohi M; Inoue Y; Tanaka K; Araki T; Mohri Y; Kusunoki M
    Anticancer Res; 2015 Oct; 35(10):5639-48. PubMed ID: 26408737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
    Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Trinh A; Trumpi K; De Sousa E Melo F; Wang X; de Jong JH; Fessler E; Kuppen PJ; Reimers MS; Swets M; Koopman M; Nagtegaal ID; Jansen M; Hooijer GK; Offerhaus GJ; Kranenburg O; Punt CJ; Medema JP; Markowetz F; Vermeulen L
    Clin Cancer Res; 2017 Jan; 23(2):387-398. PubMed ID: 27459899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer.
    Roxburgh CS; Salmond JM; Horgan PG; Oien KA; McMillan DC
    Ann Surg; 2009 May; 249(5):788-93. PubMed ID: 19387324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin in Patients with Colorectal Cancer.
    Shibutani M; Maeda K; Nagahara H; Iseki Y; Ikeya T; Hirakawa K
    Anticancer Res; 2016 Mar; 36(3):995-1001. PubMed ID: 26976989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.
    de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L
    Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.
    Hatthakarnkul P; Pennel K; Alexander P; van Wyk H; Roseweir A; Inthagard J; Hay J; Andersen D; Maka N; Park J; Roxburgh C; Thuwajit C; McMillan D; Edwards J
    J Pathol Clin Res; 2024 May; 10(3):e12374. PubMed ID: 38650367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.
    Patel M; McSorley ST; Park JH; Roxburgh CSD; Edwards J; Horgan PG; McMillan DC
    Br J Cancer; 2018 Mar; 118(5):705-712. PubMed ID: 29337962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
    Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
    J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
    Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
    Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravascular emboli relates to immunosuppressive tumor microenvironment and predicts prognosis in stage III colorectal cancer.
    Song X; Xie D; Tan F; Zhou Y; Li Y; Zhou Z; Pei Q; Pei H
    Aging (Albany NY); 2021 Aug; 13(16):20609-20628. PubMed ID: 34438367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer.
    Väyrynen JP; Väyrynen SA; Sirniö P; Minkkinen I; Klintrup K; Karhu T; Mäkelä J; Herzig KH; Karttunen TJ; Tuomisto A; Mäkinen MJ
    J Transl Med; 2019 Jun; 17(1):199. PubMed ID: 31196200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simple classifiers for molecular subtypes of colorectal cancer.
    Kim WG; Kim JY; Park DY
    Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
    Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
    Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of Glasgow Microenvironment Score as a prognostic tool in colorectal carcinoma.
    Ahuja M; Dwarak A; Mallya V; Mandal S; Tomar R; Khurana N; Lal P; Singh K
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S172-S176. PubMed ID: 37147995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.